Durable Responses in R/R DLBCL With CAR-T Product Lisocabtagene Maraleucel – Cancer Network
|
Durable Responses in R/R DLBCL With CAR–T Product Lisocabtagene Maraleucel
Cancer Network Lisocabtagene maraleucel, a CD19-directed 4-1BB CAR T-cell product, produced durable responses in patients with heavily pretreated relapsed-refractory diffuse large B cell lymphoma (R/R DLBCL) and appears to have manageable acute toxicities, … |
